According to the Zhitong Finance App, Guangkang Biochemical (300804.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 382 million yuan, a year-on-year decrease of 4.19%. Net profit attributable to shareholders of listed companies was 3.3067 million yuan, a year-on-year decrease of 88.60%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 2,8042 million yuan, a year-on-year decrease of 89.80%.
Affected by the Spring Festival holiday and the company's shutdown and maintenance, insufficient workshop capacity utilization in the first half of the year caused product unit manufacturing costs to rise. In addition, demand from some downstream customers of the company fluctuated during the reporting period, sales pace of high-margin products slowed down, and changes in product structure dragged down the company's gross margin level of original pharmaceutical products. At the same time, due to the high inventory of high-priced raw materials formed during the reporting period when oil prices rose rapidly in the previous period, the company's material costs were high in stages, and gross margin was also suppressed to a certain extent. In addition, some overseas customers have switched from purchasing raw drugs to purchasing finished formulations, which has lengthened the production and delivery cycle, and the inventory cycle for corresponding products has been extended, but this model has raised the gross profit level of pharmaceutical products to a certain extent. Combining the above factors, the average gross profit margin of the company's original pharmaceutical products in the first half of the year was 19.54%, a decrease of 6.95 percentage points over the same period last year, which had a significant impact on the company's semi-annual profit.